{"id":17119,"date":"2025-11-25T10:47:16","date_gmt":"2025-11-25T10:47:16","guid":{"rendered":"https:\/\/www.invesdor.de\/blog\/?p=17119"},"modified":"2025-11-27T12:01:41","modified_gmt":"2025-11-27T12:01:41","slug":"detect-prostate-cancer-earlier-how-pcavision-helps-patients-and-appeals-to-investors","status":"publish","type":"post","link":"https:\/\/www.invesdor.com\/blog\/detect-prostate-cancer-earlier-how-pcavision-helps-patients-and-appeals-to-investors\/","title":{"rendered":"Detect prostate cancer earlier:\u00a0How PCaVision helps patients and appeals to investors\u00a0"},"content":{"rendered":"<p class=\"has-medium-font-size\">Prostate cancer is one of the most common cancers in men. Every year, over ten million screenings are performed worldwide to detect it early. Yet today, diagnosing prostate cancer is often slow, expensive, and reliant on scarce MRI capacity. The result: long wait times, stressful uncertainty, and avoidable interventions.&#xA0;<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 ez-toc-wrap-left counter-flat ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of contents<\/p>\n<span class=\"ez-toc-title-toggle\"><\/span><\/div>\n<nav><ul class=\"ez-toc-list ez-toc-list-level-1 \"><li class=\"ez-toc-page-1\"><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.invesdor.com\/blog\/detect-prostate-cancer-earlier-how-pcavision-helps-patients-and-appeals-to-investors\/#Prostate_cancer_%E2%80%93_an_urgent_health_challenge\">Prostate cancer &#x2013; an urgent health challenge&#xA0;&#xA0;<\/a><\/li><li class=\"ez-toc-page-1\"><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.invesdor.com\/blog\/detect-prostate-cancer-earlier-how-pcavision-helps-patients-and-appeals-to-investors\/#PCaVision_streamlines_the_lengthy_diagnostic_process\">PCaVision streamlines the lengthy diagnostic process<\/a><\/li><li class=\"ez-toc-page-1\"><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.invesdor.com\/blog\/detect-prostate-cancer-earlier-how-pcavision-helps-patients-and-appeals-to-investors\/#Benefits_for_patients_clearer_less_stressful_faster_diagnosis\">Benefits for patients: clearer, less stressful, faster diagnosis&#xA0;&#xA0;<\/a><\/li><li class=\"ez-toc-page-1\"><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.invesdor.com\/blog\/detect-prostate-cancer-earlier-how-pcavision-helps-patients-and-appeals-to-investors\/#Why_this_matters_to_investors\">Why this matters to investors&#xA0;<\/a><\/li><li class=\"ez-toc-page-1\"><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.invesdor.com\/blog\/detect-prostate-cancer-earlier-how-pcavision-helps-patients-and-appeals-to-investors\/#Conclusion_why_now_may_be_the_right_time\">Conclusion: why now may be the right time&#xA0;<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n\n<p class=\"has-medium-font-size\">PCaVision offers a new way to make diagnostics more efficient, faster, and accessible. The Dutch MedTech company is developing <strong>an AI-powered prostate cancer diagnostic tool based on ultrasound<\/strong>, enabling urologists to make a diagnosis in a single session &#x2014;without MRI and without radiologists.&#xA0;<\/p>\n\n\n\n<p class=\"has-medium-font-size\">In doing so, PCaVision addresses a care gap that is only set to grow in the coming years. That&#x2019;s why this project is also compelling for investors: it combines medical benefit, impact investing in healthcare, and a scalable SaaS model with strong growth potential.&#xA0;&#xA0;<\/p>\n\n\n\n<div style=\"height:42px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Prostate_cancer_%E2%80%93_an_urgent_health_challenge\"><\/span><strong>Prostate cancer &#x2013; an urgent health challenge<\/strong>&#xA0;&#xA0;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"has-medium-font-size\"><strong>A common disease. A diagnosis that takes time and energy.&#xA0;<\/strong><\/p>\n\n\n\n<div style=\"height:42px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:33.33%\">\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"430\" height=\"465\" src=\"https:\/\/www.invesdor.de\/blog\/wp-content\/uploads\/2025\/11\/PCaVision-2.jpg\" alt=\"\" class=\"wp-image-17132\" srcset=\"https:\/\/www.invesdor.com\/blog\/wp-content\/uploads\/2025\/11\/PCaVision-2.jpg 430w, https:\/\/www.invesdor.com\/blog\/wp-content\/uploads\/2025\/11\/PCaVision-2-277x300.jpg 277w\" sizes=\"auto, (max-width: 430px) 100vw, 430px\"\/><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<p class=\"has-medium-font-size\">Prostate cancer is one of the most frequently diagnosed cancers in men. Global demand for diagnostic procedures is growing by about 10% each year. By 2040, demand is expected to double. Reasons include:&#xA0;<\/p>\n\n\n\n<ul class=\"wp-block-list has-medium-font-size\">\n<li class=\"has-medium-font-size\">An aging population&#xA0;<\/li>\n\n\n\n<li>Expanded preventive care programs&#xA0;<\/li>\n\n\n\n<li class=\"has-medium-font-size\">Growing awareness of prostate cancer screening&#xA0;<\/li>\n<\/ul>\n<\/div>\n<\/div>\n\n\n\n<div style=\"height:27px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-medium-font-size\"><strong>1. Waiting for the exam &#x2013; often for weeks<\/strong>&#xA0;<\/p>\n\n\n\n<p class=\"has-medium-font-size\">Suspected prostate cancer is stressful. Many patients wait weeks for an MRI appointment due to limited radiology capacity. This creates uncertainty and delays potential treatment.<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>2. Multiple appointments, more effort<\/strong><\/p>\n\n\n\n<p class=\"has-medium-font-size\">DThe standard process looks like this:&#xA0;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"has-medium-font-size\">Suspicion raised during a urologist visit<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"has-medium-font-size\">Referral for MRI&#xA0;<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"has-medium-font-size\">MRI result from a radiologist&#xA0;<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"has-medium-font-size\">Follow-up with the urologist&#xA0;<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"has-medium-font-size\">Targeted biopsy&#xA0;<\/li>\n<\/ul>\n\n\n\n<p class=\"has-medium-font-size\">The result: delays, extra steps, and numerous appointments.&#xA0;<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>3.<strong>Invasive procedures, often unnecessary<\/strong><\/strong>&#xA0;<\/p>\n\n\n\n<p class=\"has-medium-font-size\">The alternative to MRI is a systematic biopsy involving multiple tissue samples&#x2014;even if no clinically relevant cancer is found. This places a physical and mental burden on patients.<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>4. Capacity issues across the system<\/strong><\/p>\n\n\n\n<p class=\"has-medium-font-size\">Urology and radiology departments are already stretched thin. Overloaded diagnostic structures mean longer wait times &#xA0;and case numbers continue to rise.&#xA0;<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>In short:<\/strong> the system is reaching its limits, and the ones suffering are the men who need clarity.&#xA0;<\/p>\n\n\n\n<div style=\"height:70px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"PCaVision_streamlines_the_lengthy_diagnostic_process\"><\/span>PCaVision streamlines the lengthy diagnostic process<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"has-medium-font-size\">PCaVision accelerates diagnosis by combining AI and ultrasound. The technology is clinically validated, CE-certified, and already in use in pilot clinics.&#xA0;<\/p>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image size-large is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"1024\" src=\"https:\/\/www.invesdor.de\/blog\/wp-content\/uploads\/2025\/11\/pcavision-4-1024x1024.png\" alt=\"\" class=\"wp-image-17153\" style=\"width:344px;height:auto\" srcset=\"https:\/\/www.invesdor.com\/blog\/wp-content\/uploads\/2025\/11\/pcavision-4-1024x1024.png 1024w, https:\/\/www.invesdor.com\/blog\/wp-content\/uploads\/2025\/11\/pcavision-4-300x300.png 300w, https:\/\/www.invesdor.com\/blog\/wp-content\/uploads\/2025\/11\/pcavision-4-150x150.png 150w, https:\/\/www.invesdor.com\/blog\/wp-content\/uploads\/2025\/11\/pcavision-4-768x768.png 768w, https:\/\/www.invesdor.com\/blog\/wp-content\/uploads\/2025\/11\/pcavision-4.png 1200w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\"\/><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<p><\/p>\n\n\n\n<h3 class=\"wp-block-heading has-medium-font-size\">How does it work in practice? <\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"has-medium-font-size\">The urologist uses a standard 3D\/4D ultrasound probe<\/li>\n\n\n\n<li class=\"has-medium-font-size\">PCaVision analyzes the data automatically<\/li>\n\n\n\n<li class=\"has-medium-font-size\">The software generates a color-coded heatmap highlighting suspicious areas<\/li>\n<\/ul>\n\n\n\n<p class=\"has-medium-font-size\">The physician can perform targeted biopsies in the same session<\/p>\n<\/div>\n<\/div>\n\n\n\n<p class=\"has-medium-font-size\"><strong>A diagnostic process that used to take weeks is now completed in just 20&#x2013;30 minutes.&#xA0;<\/strong>&#xA0;<\/p>\n\n\n\n<div style=\"height:35px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Benefits_for_patients_clearer_less_stressful_faster_diagnosis\"><\/span><strong><strong>Benefits for patients: clearer, less stressful, faster diagnosis<\/strong>&#xA0;<\/strong>&#xA0;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"has-medium-font-size\"><strong>1. Faster diagnosis enables earlier treatment<\/strong><br>Many men spend weeks in uncertainty. PCaVision drastically reduces this time. Early, clear diagnoses improve the chances of detecting cancer at a treatable stage.<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>2. Less physical strain<\/strong><br>Targeted biopsies instead of &#x201C;blind&#x201D; sampling mean:&#xA0;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"has-medium-font-size\">Fewer punctures<\/li>\n\n\n\n<li class=\"has-medium-font-size\">The physician can perform targeted biopsies in the same session<\/li>\n\n\n\n<li class=\"has-medium-font-size\">Less post-procedure discomfort<\/li>\n<\/ul>\n\n\n\n<p class=\"has-medium-font-size\">Studies show unnecessary biopsies can be reduced by up to 75%.&#xA0;<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>3. No additional appointments, everything in one session<\/strong>&#xA0;<br>Patients no longer need to wait for MRI slots, organize travel to radiology centers, or coordinate multiple doctor visits. This saves time, reduces stress, and makes the process more predictable.&#xA0;<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>4. MRI-level diagnostic quality, but more accessible<\/strong>&#xA0;<br>PCaVision matches MRI in detecting clinically relevant tumors, but it&#x2019;s significantly more affordable and can be used wherever ultrasound is available.&#xA0;<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>5. Greater equity in access to care<\/strong>&#xA0;<br>In many regions, MRI access is limited. This technology enables diagnostics in places where patients previously faced long waits. For men in rural or underserved areas, that&#x2019;s a real advantage.&#xA0;<\/p>\n\n\n\n<div style=\"height:26px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-medium-font-size\"><strong>In short: PCaVision gives patients earlier clarity, reduces their burden, improves access to diagnostics and relieves the pressure on the healthcare system.&#xA0;<\/strong><\/p>\n\n\n\n<div style=\"height:43px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_this_matters_to_investors\"><\/span><strong>Why this matters to investors<\/strong>&#xA0;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"has-medium-font-size\">Because patient benefits are directly tied to economic potential. The bigger the medical problem, the stronger the market and the clearer the need for a better solution.&#xA0;<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>1. A large, growing market<\/strong>&#xA0;<br>Over 10 million diagnostic procedures globally each year&#xA0;<br>Growth: ~10% annually&#xA0;<br>By 2040: expected to double&#xA0;<\/p>\n\n\n\n<p class=\"has-medium-font-size\">This is a huge market, and PCaVision addresses a critical bottleneck.&#xA0;<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>2. A solution that truly relieves the system<\/strong>&#xA0;<br>The technology shortens diagnostic times from weeks to minutes. That means real capacity gains, cost reduction, and higher efficiency.&#xA0;<\/p>\n\n\n\n<p class=\"has-medium-font-size\">For clinics, that translates to:&#xA0;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"has-medium-font-size\">Faster workflows&#xA0;<\/li>\n\n\n\n<li class=\"has-medium-font-size\">Less dependency on MRI&#xA0;<\/li>\n\n\n\n<li class=\"has-medium-font-size\">Economic benefits&#xA0;<\/li>\n<\/ul>\n\n\n\n<p class=\"has-medium-font-size\">A product that cuts costs while improving care quality has strong chances for widespread adoption.&#xA0;<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>3. A scalable SaaS business model<\/strong>&#xA0;<br>PCaVision earns per scan, not per device. That means:&#xA0;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"has-medium-font-size\">Recurring revenue&#xA0;<\/li>\n\n\n\n<li class=\"has-medium-font-size\">Predictable income&#xA0;<\/li>\n\n\n\n<li class=\"has-medium-font-size\">High margins&#xA0;<\/li>\n\n\n\n<li class=\"has-medium-font-size\">Low variable costs&#xA0;<\/li>\n\n\n\n<li class=\"has-medium-font-size\">Strong scalability&#xA0;<\/li>\n<\/ul>\n\n\n\n<p class=\"has-medium-font-size\">Every clinic becomes a long-term revenue driver.&#xA0;<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>4. Clinically validated, CE-certified, early customers onboard<\/strong>&#xA0;<br>The company is no longer a research project, it&#x2019;s a product in the market. This maturity reduces tech risk for investors.&#xA0;<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>5. Strong institutional backers<\/strong>&#xA0;<br>The Series A is supported by:&#xA0;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"has-medium-font-size\">NLC Health Impact Fund&#xA0;<\/li>\n\n\n\n<li class=\"has-medium-font-size\">CbusineZ&#xA0;<\/li>\n\n\n\n<li class=\"has-medium-font-size\">TU\/e Holding<\/li>\n\n\n\n<li class=\"has-medium-font-size\">Family offices and experienced angel investors&#xA0;<\/li>\n<\/ul>\n\n\n\n<p class=\"has-medium-font-size\">Private investors participate via Invesdor on the same preferred share terms as these institutional investors, meaning equal economic rights.&#xA0;<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>6. Impact investing with measurable value<\/strong>&#xA0;<br>This healthcare technology:&#xA0;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"has-medium-font-size\">Speeds up diagnoses&#xA0;<\/li>\n\n\n\n<li class=\"has-medium-font-size\">Reduces unnecessary procedures<\/li>\n\n\n\n<li class=\"has-medium-font-size\">Improves access to care&#xA0;&#xA0;<\/li>\n\n\n\n<li class=\"has-medium-font-size\">Relieves pressure on healthcare systems&#xA0;<\/li>\n<\/ul>\n\n\n\n<p class=\"has-medium-font-size\">&#x2026; fulfilling SDG 3: &#x201C;Good Health and Well-being.&#x201D;&#xA0;<br><br>Investing in PCaVision means tackling a socially relevant problem, with potential for financial upside.<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>7. Attractive exit options in MedTech<\/strong>&#xA0;<br>MedTech companies with strong clinical evidence and scalable models are frequently acquired. Potential outcomes include:&#xA0;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"has-medium-font-size\">Strategic acquisition by imaging or diagnostics giants&#xA0;<\/li>\n\n\n\n<li class=\"has-medium-font-size\">Series B funding at a higher valuation<\/li>\n\n\n\n<li class=\"has-medium-font-size\">Regional licensing or distribution partnerships&#xA0;<\/li>\n<\/ul>\n\n\n\n<p class=\"has-medium-font-size\">As market adoption grows, so does company value and investor potential.&#xA0;<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>What matters<\/strong>: <\/p>\n\n\n\n<p class=\"has-medium-font-size\">Investing in growth companies carries risk, including total loss.&#xA0;<br>At the same time, this market often offers a compelling risk-reward ratio.&#xA0;<\/p>\n\n\n\n<p class=\"has-medium-font-size\">A rational checklist:&#xA0;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"has-medium-font-size\">Is the market big enough? &#x2192; Yes: growing, driven by demographics and medical need&#xA0;<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"has-medium-font-size\">Does the company solve a real problem? &#x2192; Yes: a genuine and growing care gap&#xA0;<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"has-medium-font-size\">Is the product validated and market-ready? &#x2192; Yes: CE-certified, early clinics onboard, strong data&#xA0;<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"has-medium-font-size\">Is the business model scalable? &#x2192; Yes: SaaS with recurring revenue&#xA0;<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"has-medium-font-size\">Are experienced investors involved? &#x2192; Yes: institutional and strategic partners&#xA0;<\/li>\n<\/ul>\n\n\n\n<p class=\"has-medium-font-size\">For many investors, PCaVision is compelling: it combines medical value, measurable impact, and a scalable tech model, a rare combination in the MedTech space.&#xA0;<\/p>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion_why_now_may_be_the_right_time\"><\/span><strong>Conclusion: why now may be the right time<\/strong>&#xA0;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"has-medium-font-size\">PCaVision is at the intersection of technology, market, and timing. The clinical evidence is strong, early adopters are in place, the product is ready and the healthcare problem is only growing.&#xA0;<\/p>\n\n\n\n<p class=\"has-medium-font-size\">Those looking to invest in companies that:&#xA0;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"has-medium-font-size\">Drive medical progress&#xA0;<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"has-medium-font-size\">Address real care gaps&#xA0;<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"has-medium-font-size\">Offer clear growth potential&#xA0;<\/li>\n<\/ul>\n\n\n\n<p class=\"has-medium-font-size\">&#x2026; will find in PCaVision a project with clear relevance and solid foundations.&#xA0;<\/p>\n\n\n\n<div style=\"height:35px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div style=\"height:35px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-cyan-bluish-gray-color has-alpha-channel-opacity has-cyan-bluish-gray-background-color has-background is-style-wide\">\n\n\n\n<p><\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Find out more now and invest in MedTech: your opportunity to help shape the future!&#xA0;<\/h3>\n\n\n\n<p><\/p>\n\n\n\n<p class=\"has-medium-font-size\">&#x1F449; <strong>Visit <a href=\"https:\/\/www.invesdor.com\/rounds\/1203a80b-ea4e-4c01-8a98-9963c5b41fc7#\/\" target=\"_blank\" rel=\"noopener\" title=\"\">PCaVision&#x2019;s investment page<\/a><\/strong>&#xA0;<\/p>\n\n\n\n<p><em>Disclaimer: Please read the risk disclosures and documentation carefully. Investing in securities of growth companies can result in a total loss of invested capital.<\/em><br><\/p>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-cyan-bluish-gray-color has-alpha-channel-opacity has-cyan-bluish-gray-background-color has-background is-style-wide\">\n\n\n\n<div style=\"height:39px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Prostate cancer is one of the most common cancers in men. Every year, over ten million screenings are performed worldwide to detect it early. Yet today, diagnosing prostate cancer is often slow, expensive, and reliant on scarce MRI capacity. The result: long wait times, stressful uncertainty, and avoidable interventions.&#xA0; PCaVision &#x2026;<\/p>\n","protected":false},"author":50,"featured_media":17102,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[83,121,129,91],"tags":[],"class_list":["post-17119","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-featured-en","category-general","category-investment-projects","category-market-companies"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.invesdor.com\/blog\/wp-json\/wp\/v2\/posts\/17119","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.invesdor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.invesdor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.invesdor.com\/blog\/wp-json\/wp\/v2\/users\/50"}],"replies":[{"embeddable":true,"href":"https:\/\/www.invesdor.com\/blog\/wp-json\/wp\/v2\/comments?post=17119"}],"version-history":[{"count":31,"href":"https:\/\/www.invesdor.com\/blog\/wp-json\/wp\/v2\/posts\/17119\/revisions"}],"predecessor-version":[{"id":17186,"href":"https:\/\/www.invesdor.com\/blog\/wp-json\/wp\/v2\/posts\/17119\/revisions\/17186"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.invesdor.com\/blog\/wp-json\/wp\/v2\/media\/17102"}],"wp:attachment":[{"href":"https:\/\/www.invesdor.com\/blog\/wp-json\/wp\/v2\/media?parent=17119"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.invesdor.com\/blog\/wp-json\/wp\/v2\/categories?post=17119"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.invesdor.com\/blog\/wp-json\/wp\/v2\/tags?post=17119"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}